Catheter Production Articles & Analysis: Older
9 news found
MedSource Labs Moves the Needle in the Peripheral Safety IV Market With the announcement of ClearSafe Comfort® and TrueSafe Comfort® Blood Control IV Catheters with groundbreaking active check valve ...
“The acquisition of MateraCor, Inc., and their lead product, Trans-Catheter Myocardial Restoration (TCMR), reinforces our position to treat left ventricular heart failure by offering a variety of solutions that will directly impact ventricular remodeling through less invasive LV restoration ...
The company’s portfolio comprises two core products, the Walrus Balloon Guide Catheter (BGC) system, and the Wahoo Control™ Catheter hybrid access system. ...
Business Development In April 2021, the Company entered into an agreement with a Japanese therapeutic partner related to the Helix biotherapeutic delivery product candidates. Under the terms of the agreement, BioCardia received $500,000, a portion of which is creditable for biotherapeutic delivery products and support services. The agreement has a one-year ...
The company’s portfolio comprises two core products, the Walrus Balloon Guide Catheter (BGC) system, and the Wahoo Control™ Catheter hybrid access system. ...
The company’s portfolio comprises two core products, the Walrus Balloon Guide Catheter (BGC) system, and the Wahoo Control™ Catheter hybrid access system. ...
Without this feature of post deployment, on demand shape changing, to achieve a similar pitch of the impeller blade would require a housing catheter as large as 22 FR size. This shape memory twist allows the device to be deployed through a considerably smaller, 13.8FR catheter. ...
” Richardson further stated, “These studies, again, give evidence to the advantages of the unique design for our catheter-based product. Furthermore, we have adapted this same mechanical stent and impeller pump platform for use in our chronic wireless device, which we are actively building and testing, to target additional therapeutic ...
(“Orchestra BioMed” or the “Company”), a biomedical innovation company developing transformative therapeutic products for large unmet needs in procedure-based medicine, today announced the appointment of Bob Laughner, an expert in global regulatory affairs for combination products, as Vice President, Regulatory Affairs. ...